Toray Develops Porous Fiber Technology for Adsorbing Pathogenic Substances in Intractable Diseases
NQ Score
51/100
AI Summary (NQ-processed)
Toray has developed a technology to control the pore size of PMMA porous fibers up to 1,000nm, enabling the selective removal of high-molecular-weight pathogenic substances. The technology aims to provide new blood purification treatment options for intractable diseases such as autoimmune disorders and cancer.
AI analysis data is not yet available.
Frequently Asked Questions
- Q: What types of diseases can this technology help treat?
- A: It is intended for blood purification therapies for intractable diseases such as autoimmune disorders, cardiovascular metabolic diseases, neurodegenerative diseases, and cancer.
- Q: How does it differ from conventional fibers?
- A: It enables control of pore sizes up to approximately 1,000nm, which is more than 50 times larger than conventional capabilities, allowing for the removal of previously uncapturable high-molecular-weight pathogenic substances.